Low urine IL-16 at 12 months predicted kidney survival much better than proteinuria. Check out AUCs in the this first slide. Dr. @andreafava reviews this potential biomarker. Question if this could also be a possible target for treatment as well? #RNL2024 @RheumNow https://t.co/cCLRERVXmq

Low urinary IL16 levels at 12 months predicts kidney suvial at 3 years better than proteinuria - @Andreafava @rheumnow #RNL2024 https://t.co/AEaL8n2nv8

@andreafava @jhrheumatology Urinary biomarkers (CD163, IL-16) at 3 months predict the 1 year response better than UPCR - At 6 & 12 mos predicts renal survival at 3 yrs - At 12 mos: IL-16 92% accurate, sens 97%, Spec 80% vs UPCR 72% accurate, 75% sens, spec 67% #ACR2024 @RheumNow https://t.co/YtbCrwrch0

Scary! A third of patient with lupus nephritis who are considered complete respondues continue to aaccrue progressive renal damage - @Andreafava @rheumnow #RNL2024 https://t.co/mhu3YoY3YV

1/3 of lupus nephritis patient classified as "complete responders" continued to accrue progressive renal damage despite resolution of proteinuria over 1 year. Dr. @andreafava reviews GFR trajectories after renal bx at #RNL2024 @RheumNow https://t.co/nYJZWw9jUL

Myeloid and neutrophil degranulation is involved in disease activation of lupus nephritis. IL16 and CD163 are urinary biomarkers correlating with histologic disease activity “- Dr. @andreafava #RNL2024 @rheumnow https://t.co/YffIRy8B9u

Urine proteomics in lupus nephritis IL-16 and CD163 are urinary biomarkers most correlated w/ histologic activity Myeloid & degranulation sign ass w histo activity -> PR3+cells abundant in LN @andreafava #RNL2024 @RheumNow https://t.co/AVkZxPXkw3

@andreafava reviews options other than renal biopsy in the future of Lupus renal disease. Urine proteomics can detect LN active pathways IL-16, proinflammatory chemokine, linked to LN activity as potential new biomarker? #RNL2024 @RheumNow https://t.co/GoEwu09npd

Proteinuria does NOT correlate with intrarenal activity. Additionally, initial bx was not predictive of ESKD. Dr. Andrea Fava discusses need for second bx but difficulty doing so ie: it's invasive, it has risk, etc. #RNL2024 @RheumNow @andreafava https://t.co/1E5uuBGsO9

“90% of repeat biopsy will lead to change in treatment. Get the 2nd biopsy” – Dr. A Fava #RNL2024 @rheumnow https://t.co/wLaZelSeFo

@andreafava: 57% of pts w/ lupus nephritis are asymptomatic Screen w/ proteinuria- but does NOT correlate w/ intrarenal disease - Cannot differentiate classes, lagging indicator, does not distinguish inflammation from damage 87% repeat Bx lead to change in Rx #RNL2024 @RheumNow https://t.co/de66VSKUG1

“50% of pts with lupus nephritis are asymptomatic . You have to have a degree of kidney damage before you have proteinuria. Proteinuria does not correlate with intrarenal activity.” – Dr. A Fava #RNL2024 @rheumnow https://t.co/9aHmLG6VjA